Kymera therapeutics logo. Kymera logo png vector transparent.
Kymera therapeutics logo. The Watertown, Massachusetts Oct 24, 2025 · KYMR | Complete Kymera Therapeutics Inc. stock news by MarketWatch. , 2nd Floor, Cambridge, MA 02139,UNITED STATES. Download free Kymera vector logo and icons in PNG, SVG, AI, EPS, CDR formats. 00. , a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The expanded Phase II programs for KT-474 in Find the latest Financials data for Kymera Therapeutics, Inc. Jan 17, 2025 · Faisal Khurshid has given his Buy rating due to a combination of factors including Kymera Therapeutics’ strategic development plans and strong financial position. Join us at Kymera Therapeutics, where our values and commitment to improving patients’ lives guide our work to develop novel medicines. 's business for stockholders, potential investors, and financial analysts. Jun 11, 2025 · Our Company Leading the Charge for Transformative Therapeutics Kymera is a clinical-stage biotechnology company working to reinvent the treatment of human disease through the development of innovative, highly differentiated medicines that address critical health problems and dramatically improve patients’ lives. He also serves on the board of Magenta Therapeutics (NASDAQ: MGTA) and several seed-stage companies. Search results for kymera logo png icon vector. Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Mar 12, 2020 · Pegasus™ is Kymera Therapeutics' proprietary protein degradation platform, created by its team of experienced drug hunters to improve the effectiveness of targeted protein degradation and See the company profile for Kymera Therapeutics, Inc. (KYMR) stock, including real-time price, chart, key statistics, news, and more. View the latest KYMR financial statements, income statements and financial ratios. Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation. A partnership with Sanofi includes potential Jan 7, 2025 · Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to Aug 20, 2024 · Kymera Therapeutics Announces Pricing of $225 Million Public Offering August 19, 2024 22:45 ET | Source: Kymera Therapeutics, Inc. It has several programs in development, including IRAK4, IRAKIMiD, STAT3, and MDM2, for the treatment of various diseases such as immunology-inflammation diseases, hematologic malignancies, solid Aug 14, 2024 · Vikram Purohit’s rating is based on the comprehensive evaluation of Kymera Therapeutics’ pipeline advancements and strategic decisions. (KYMR) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives Working at Kymera Therapeutics Reviews show: 🏢 Culture – The company fosters a welcoming and energizing onsite atmosphere, although maintaining work-life balance can be challenging due to a demanding culture. As we celebrate Kymera’s five-year anniversary, I look back and reflect on the inspiration and purpose behind Kymera’s founding, the progress we have made over these five years, and The Investor Relations website contains information about Kymera Therapeutics, Inc. , Jan. Late mid-stage trials once dosage levels are chosen probably don't begin until 2027, with Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. The latest application filed is for "IRAKIMID" Company Profile Find the perfect kymera therapeutics stock photo, image, vector, illustration or 360 image. The shares could trade up 75% in a bull case on KT Logo is a canadian trademark and brand of Kymera Therapeutics, Inc. MassBioEd partners with the LEAH project and LabCentral to offer a lab-based summer internship Nov 6, 2024 · In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a price target of $53. Mar 15, 2022 · Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials. Sep 17, 2025 · Resource Library Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies. Embrace the season in comfort. Aug 21, 2024 · WATERTOWN, Mass. Aug 6, 2024 · On August 7, Kymera Therapeutics will report latest earnings. Aug 21, 2023 · A group of aspiring young scientists got a glimpse inside a Watertown company that does cutting-edge biopharmaceutical research. Logo Holiday Sweaters. The high school age students recently visited Kymera Therapeutics‘ offices and labs at Arsenal Yards as part Jun 25, 2025 · Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday. Kymera’s breakthrough therapeutics hijack and redirect the ubiquitin proteosome system (UPS), central to the regulation of cellular processes and the molecular biology of protein May 14, 2025 · Kymera stock downgraded to 'Hold': Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Since its founding, Kymera has built a preeminent discovery engine capable of identifying new drug candidates at an accelerated pace. Common Stock (KYMR) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using Aug 21, 2020 · Kymera Therapeutics, Inc. The company has outlined a Dec 2, 2024 · Wells Fargo analyst Derek Archila upgraded Kymera Therapeutics (KYMR) to Overweight from Equal Weight with a price target of $57, up from $38. (KYMR) stock quote, history, news and other vital information to help you with your stock trading and investing. Follow Kymera Therapeutics stock price in real-time here. This trademark was filed to the Canadian Intellectual Property Office on Wednesday, May 22, 2019. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the Kymera is a pioneer and innovator in the TPD field – throughout the drug discovery process, all our projects share a strong and clear focus on inventing better therapeutics using our unique approach and ultimately addressing unmet needs for patients. (GILD) said on Wednesday that it entered into an exclusive option and license agreement with biotech company Kymera Therapeutics, Inc. Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients Sanofi and Aetion launch enterprise-wide collaboration to advance regulatory submissions using real-world evidence Sanofi and Aetion launch enterprise-wide collaboration to advance regulatory submissions using real-world evidence Nov 5, 2024 · About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and Aug 29, 2023 · By Charlie Breitrose, Watertown News August 21, 2023 A group of aspiring young scientists got a glimpse inside a Watertown company that does cutting-edge biopharmaceutical research. Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Bruce is Chairman and Co-founder of Nimbus Therapeutics and General Partner at Atlas Venture. , a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Download Kymera Therapeutics Inc. Jul 9, 2020 · While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera Therapeutics. pngFormat PNG Mar 31, 2023 · Kymera Perspectives Hear from our team on recent breakthroughs, scientific and clinical advancements, company culture, and our ongoing work to develop new medicines at Kymera. , Watertown, MA 02472,UNITED STATES. Feb 19, 2025 · The challenge around Kymera Therapeutics is the company is many years from potential commercialization. All Rights Reserved. Kymera’s seasoned leaders bring the insights and experience needed to accelerate progress and change patient lives. Jan 14, 2025 · Kymera Therapeutics (NASDAQ:KYMR) is making waves, with its stock climbing nearly 10% after the company laid out a bold strategy for 2025. Stay warm and stylish with Kymera Therapeutics, Inc. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. Data from a Phase 1 study in healthy volunteers showed that all dose levels of Kymera is a biotechnology company working to reinvent the treatment of human disease through the development of innovative, highly differentiated medicines. Jun 7, 2021 · Kymera was founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of a powerful new class of medicines based on targeted protein degradation (TPD). Kymera logo png vector transparent. Aug 6, 2023 · Kymera Therapeutics ended the second quarter with over $470 million in cash and marketable securities, providing a cash runway into 2H25. Trusted executive recruitment in investor relations, corporate communications, finance, and HR. KT-621 Phase 1 healthy volunteer trial ongoing Aug 21, 2020 · About Kymera Therapeutics Kymera Therapeutics (NASDAQ: KYMR) is a clinical-stage biotechnology company that focuses on developing medicines through targeted protein degradation. Cells naturally clear out misfolded or accumulated proteins; at Kymera we create heterobifunctional small molecules that redirect this natural process by engaging enzymes called E3 ubiquitin ligases to recruit disease-causing proteins and place a chain of ubiquitin molecules on the recruited protein. May 21, 2024 · NEOsphere Biotechnologies GmbH, a German biotechnology company pioneering high-throughput proteomics to systematically build broad and unique portfolios of novel degrader targets at scale, announced a collaboration with Kymera Therapeutics, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using Nov 30, 2021 · --Kymera Therapeutics, Inc. Jan 14, 2025 · Kymera Therapeutics (KYMR) announced its corporate goals for 2025, including anticipated progress on its clinical pipeline of immunology programs. Available for both RF and RM licensing. Oct 18, 2022 · Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. Find the latest Kymera Therapeutics, Inc. Having advanced the first degrader into the clinic for Aug 18, 2020 · Kymera Therapeutics, Inc. -- (BUSINESS WIRE)-- Gilead Sciences, Inc. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule programs designed to harness the body’s innate protein recycling machinery to degrade Kymera Therapeutics, Inc. & WATERTOWN, Mass. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. Partner with us for tailored hiring solutions and industry market insights. Kymera Therapeutics, Inc. Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies. The company is concentrating its resources Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. Feb 28, 2025 · H. (NASDAQ:KYMR)创立于2015年，总部位于美国马萨诸塞州 Watertown，全职雇员55人，是一家生物制药公司，致力于发现和开发新颖的小分子疗法，该疗法通过利用人体自身的天然蛋白质降解系统来选择性降解致病蛋白质。 Jul 31, 2024 · About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and . Find the latest analyst research for Kymera Therapeutics, Inc. Oct 31, 2024 · Marc Frahm has given his Buy rating due to a combination of factors surrounding Kymera Therapeutics’ strategic focus and promising clinical trial data. Powered by a proprietary predictive modeling capability and a game-changing integrated degradation ©2021 KYMERA THERAPEUTICS, INC. . View real-time stock prices and stock quotes for a full financial overview. The ubiquitin tag is recognized by the cell’s recycling systems—the proteasome—to Discover how TPD is opening new therapeutic opportunities and learn about Kymera’s current clinical trials. View Nello Mainolfi’s profile on LinkedIn, a professional Kymera Therapeutics Inc. Spurred by the growth of both their research operations and their pool of talent, Kymera engaged OTJ Nov 2, 2023 · Targeted IRAK4 protein degrader KT-413 did exactly what it was supposed to in an early-stage clinical trial, but Kymera Therapeutics is still jettisoning the program. The high school age students recently visited Kymera Therapeutics‘ offices and labs at Arsenal Yards as part of a field trip organized by MassBioEd’s Summer Program. 681. You can download in PNG Information on stock, financials, earnings, subsidiaries, investors, and executives for Kymera Therapeutics. Kymera Therapeutics Inc. Annual stock financials by MarketWatch. The company specializes in creating small-molecule therapies that target disease drivers, with an emphasis on immunological diseases and oncology programs. Nov 16, 2022 · PNG Logo Vector Brand Downloads (SVG, EPS) Graphic Design Elements (AI, EPS, SVG, PDF, PNG, Transparent) Home Page Background Flag Icon Logo Silhouette Vector Trademark applications and grants for Kymera Therapeutics, Inc. Jun 25, 2025 · Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 DegradersFOSTER CITY, Calif. Wall Street analysts are expecting losses per share of $0. Common Stock (KYMR) at Nasdaq. This trademark was filed to the Canadian Intellectual Property Office on Thursday, May 6, 2021. Click to read why KYMR stock is a Hold. Feb 12, 2025 · Read news and insights on how Kymera is advancing a new class of small molecule medicines using targeted protein degradation. This is a pivotal year for Jan 9, 2024 · WATERTOWN, Mass. He is also currently Chairman of Arkuda Therapeutics, AvroBio (NASDAQ: AVRO), Hotspot Therapeutics, Kymera Therapeutics (NASDAQ: KYMR), and Quench Bio. Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. Read more here. The company’s Nov 15, 2015 · · Experience: Kymera Therapeutics · Education: Imperial College London · Location: Greater Boston · 500+ connections on LinkedIn. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. Wainwright lowered the firm’s price target on Kymera Therapeutics (KYMR) to $54 from $60 and keeps a Buy rating on the shares. Jun 13, 2025 · Kymera Therapeutics, Inc. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Kymera Therapeutics is pioneering a game-changing new therapeutic modality and platform with the potential to transform drug discovery and deliver breakthrough medicines for previously untreatable diseases. Jul 16, 2024 · Kymera Therapeutics is a protein degradation specialist drug developer with promising Phase 1 and 2 stage protein degraders targeting various diseases. Kymera Feb 26, 2025 · About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and KYMR | Complete Kymera Therapeutics Inc. advanced stock charts by MarketWatch. PAGE 3 •Kymera –introduction and pipeline •IRAK4 degrader KT-474 and clinical degrader proof of mechanism •Classical undruggable -STAT3 degradation and potential •Summary Outline ©2021 KYMERA THERAPEUTICS, INC. Jun 2, 2025 · An experimental protein-degrading drug from Kymera Therapeutics appeared safe and able to affect its intended target in an early-stage clinical trial, leading shares in the biotechnology company to climb by nearly 50%. has 13 trademark applications. Kymera’s pipeline is focused on validated disease targets where protein degradation is the best or only way to improve the standard of care. C. Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to Find the Kymera Therapeutics style guide with brand assets such as logos, colors, fonts, and more. Logo is a canadian trademark and brand of Kymera Therapeutics, Inc. Kymera's approach aims to provide treatments for conditions Feb 20, 2025 · Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to Kymera Therapeutics is a biopharmaceutical company that develops small molecule therapeutics to selectively degrade disease-causing proteins by using the body's natural protein degradation system. 500 North Beacon Street, 4th Floor, Watertown, MA 02472 © 2025 Kymera Therapeutics, Inc. Use the PitchBook Platform to explore the full profile. stock data: historical KYMR stock prices from MarketWatch. The firm cites the company’s pipeline development programs Jul 9, 2024 · Kymera Therapeutics shares jumped Tuesday, a day after it said partner Sanofi agreed to expand research into its experimental treatment for skin diseases. com. was incorporated in 2015 and is headquartered in Watertown, Massachusetts. View KYMR historial stock data and compare to other stocks and exchanges. At Kymera International, we are global leaders in the specialty materials field manufacturing industrial coatings that are shaping the future. 💰 Compensation – Salaries are competitive within the biotech industry, with many employees appreciating the benefits offered despite recent reductions in options like unlimited Apr 22, 2025 · Kymera Therapeutics (KYMR) announced that it recently initiated dosing in its BroADen Phase 1b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients Aug 19, 2024 · Kymera Therapeutics Announces Proposed Public Offering August 19, 2024 16:01 ET | Source: Kymera Therapeutics, Inc. We are advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. analyst estimates, including KYMR earnings per share estimates and analyst recommendations. We have 1 free kymera logo png, transparent logos, vector logos, logo templates and icons. Get premium, high resolution news photos at Getty Images 3 days ago · A detailed overview of Kymera Therapeutics, Inc. The spotlight is on KT-621, its first-in-class oral STAT6 Jul 2, 2025 · Gilead Sciences, Inc. (KYMR) to accelerate the development and commercialization of a class of drugs with potential use in cancer treatment. Jun 25, 2025 · Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader alongside details of the selection of a follow-up prospect and a $750 Kymera-Logo-RGB-Denim+Marigold - High Res. , Aug. PAGE 4 Kymera: A Leading TPD Company Recreate LOGO VISION KEY PARTNERSHIPS INITIAL FOCUS In this photo illustration, the Kymera Therapeutics logo is seen displayed on a smartphone screen. 5 days ago · Discover Nurix Therapeutic's targeted protein degradation platform, combining degraders and DACs to transform cancer and autoimmune disease treatment. jg zy nmskz rfsh3 5jkuer pumvf oapctjgh xiss6 sfsuq4 lfi